Skip to main content

Welcome to Janssen United States

VISIT JANSSEN GLOBAL

Press Releases

Jan 29, 2015

HORSHAM, PA

U.S. FDA Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia: First FDA-Approved Therapy for This Disease

Jan 14, 2015

RARITAN, NJ

Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO®

Dec 05, 2014

RARITAN, NJ

Janssen Teaming Up to Take On Diabetes

Nov 13, 2014

TITUSVILLE, NJ

U.S. FDA Approves Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) for the Treatment of Schizoaffective Disorder

Nov 05, 2014

TITUSVILLE, NJ

OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection

Oct 20, 2014

RARITAN, NJ

Janssen Pharmaceuticals and Diabetes Hands Foundation Encourage People with Type 2 Diabetes to Get Moving for National Diabetes Month

Sep 24, 2014

TITUSVILLE, NJ

Study Observed Association between JANSSEN® CONNECT® Injection Centers and Increased Adherence to Healthcare Provider-Ordered Janssen Long-Acting Treatment for People with Schizophrenia

Aug 08, 2014

RARITAN, NJ

U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

Jul 28, 2014

HORSHAM, PA

IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p

Jul 14, 2014

TITUSVILLE, NJ

Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies